Paul Beringer

Professor and Chair

University of Southern California

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor and Chair Paul Beringer is affiliated with the University of Southern California. His research focuses on pharmacokinetics and drug interactions, particularly in relation to cystic fibrosis and lung transplantation. Recent publications include studies on the in vitro activity of antimicrobial agents and the modeling of drug-drug interactions involving CFTR modulators. His work aims to enhance therapeutic strategies and safety for patients with complex medical needs.

Articles (12)

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (3)

Julio A. Camarero

University of Southern California

UNITED STATES

View details

Eunjin Hong

University of Southern California

UNITED STATES

View details

J. Neman

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Paul Beringer

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Evaluation of Complex Drug Interactions Between Elexacaftor-Tezacaftor-Ivacaftor and Statins Using Physiologically Based Pharmacokinetic Modeling

In Vitro Activity of Imipenem/Relebactam Alone and in Combination Against Cystic Fibrosis Isolates of <i>Mycobacterium abscessus</i>

Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients

Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: mechanistic exploration through physiologically-based pharmacokinetic modeling and a clinical case series.

Physiologically Based Pharmacokinetic Modeling To Guide Management of Drug Interactions between Elexacaftor-Tezacaftor-Ivacaftor and Antibiotics for the Treatment of Nontuberculous Mycobacteria.

Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19.

Preclinical Pharmacokinetics and Safety of Intravenous RTD-1.

Chemical Synthesis of a Potent Antimicrobial Peptide Murepavadin Using a Tandem Native Chemical Ligation/Desulfurization Reaction.

Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.

Anti-Inflammatory Effects of RTD-1 in a Murine Model of Chronic <i>Pseudomonas aeruginosa</i> Lung Infection: Inhibition of NF-κB, Inflammasome Gene Expression, and Pro-IL-1β Biosynthesis

Engineered Cyclotides with Potent Broad in Vitro and in Vivo Antimicrobial Activity.

Collaborators (3)

Julio A. Camarero

Eunjin Hong

J. Neman

Make your next move.